Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LinkDoc Technology (Beijing) Co. Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer
The is a multi-center retrospective study. Patients with pathologic N2 NSCLC who underwent VATS or open lobectomy between 2014 and 2017 were included into this study. Clinical data on patient demographic, clinical characteristics, treatment and clinical outcomes will be collected to evaluate the safety and effectiveness of video-assisted thoracoscopic lobectomy for pathologic N2 NSCLC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VATS lobectomy | Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery |
| |
| Thoracotomy lobectomy | Pathologic N2 NSCLC patients who received lobectomy by thoracotomy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VATS lobectomy | Procedure | Patients who received lobectomy by video-assisted thoracoscopic surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival | 2014-2018 |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of hospital stay [Perioperative outcomes] | Duration of hospital stay [Perioperative outcomes] | 2014-2017 |
| Postoperative 30 and 90 days [Perioperative outcomes] | Postoperative 30 and 90 days [Perioperative outcomes] |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survivals in the subgroups stratified by T staging | Overall survivals in the subgroups stratified by T staging | 2014-2018 |
| Overall survivals in the subgroups stratified by neoadjuvant therapy | Overall survivals in the subgroups stratified by neoadjuvant therapy |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Pathologically diagnosed N2 non-small cell lung cancer who received VATS or thoracotomy lobectomy between 2014 and 2017
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Xiaofei Li, PhD | Tang-Du Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China-Japan Friendship Hospital | Beijing | Beijing Municipality | 100029 | China | ||
| China PLA General Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Thoracotomy lobectomy | Procedure | Patients who received lobectomy by thoracotomy |
|
| 2014-2017 |
| Drainage time [Perioperative outcomes] | Drainage time [Perioperative outcomes] | 2014-2017 |
| Intraoperative blood loss [Perioperative outcomes] | Intraoperative blood loss [Perioperative outcomes] | 2014-2017 |
| Postoperative complications [Perioperative outcomes] | Postoperative complications [Perioperative outcomes] | 2014-2017 |
| 2014-2018 |
| Overall survivals in the subgroups stratified by number of lymph node station involved | Overall survivals in the subgroups stratified by number of lymph node station involved | 2014-2018 |
| Impact factors for overall survival | Impact factors for overall survival | 2014-2018 |
| Impact factors for postoperative mortality within 30/90 days | Impact factors for postoperative mortality within 30/90 days | 2014-2017 |
| Propensity score matching analysis of overall survival | Propensity score matching analysis of overall survival | 2014-2018 |
| Propensity score matching analysis of perioperative outcomes | Propensity score matching analysis of perioperative outcomes | 2014-2018 |
| Propensity score matching analysis of impact factors for overall survival | Propensity score matching analysis of impact factors for overall survival | 2014-2018 |
| Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days | Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days | 2014-2018 |
| Beijing |
| Beijing Municipality |
| 100853 |
| China |
| Henan Cancer Hospital | Zhengzhou | Henan | 450003 | China |
| Tongji Hospital Affiliated to Huazhong Technology Hospital | Wuhan | Hubei | 430030 | China |
| Jiangsu cancer hospital | Nanjing | Jiangsu | 210009 | China |
| Xi'an Tangdu Hospital | Xi'an | Shaanxi | 710000 | China |
| Shanghai Chest Hospital | Shanghai | Shanghai Municipality | 200030 | China |
| Huaxi Hospital Affiliated to Sichuan University | Chengdu | Sichuan | 610041 | China |
| Tianjin Chest Hospital | Tianjin | Tianjin Municipality | 300051 | China |
| First Hospital Affiliated to Zhejiang University | Hangzhou | Zhejiang | 310003 | China |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided